Biogen Management
Management Kriterienprüfungen 3/4
Biogen CEO ist Chris Viehbacher , ernannt in Nov 2022, hat eine Amtszeit von 3.83 Jahren. Die jährliche Gesamtvergütung beträgt $23.65M , bestehend aus 7.3% Gehalt und 92.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.02% der Aktien des Unternehmens, im Wert von $6.48M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.6 Jahre bzw. 4.5 Jahre.
Wichtige Informationen
Chris Viehbacher
Geschäftsführender
US$23.6m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 7.31% |
| Amtszeit als Geschäftsführer | 3.8yrs |
| Eigentum des Geschäftsführers | 0.02% |
| Durchschnittliche Amtszeit des Managements | 3.6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.5yrs |
Jüngste Management Updates
Recent updates
Seeking Alpha • Sep 17
Biogen: Growth Is Back, But It Came At A Price
Summary Biogen's shift toward newer products (Leqembi, Skyclarys) and the Apellis acquisition have successfully restored top-line growth. Weighted target price of ~$214 offers minimal upside relative to current levels; maintaining a Hold rating. The key challenge now is execution: Biogen must translate revenue growth into higher margins and cash flow while reducing acquisition-related debt and delivering on its pipeline. Read the full article on Seeking Alpha
Narrative-Update • Sep 17
BIIB: Alzheimer’s Safety And Dose Questions Will Likely Cap Re Rating Potential
Biogen's analyst price target has been revised higher to $186.31 from $180.58, with analysts pointing to updated views on its late stage pipeline, the lupus opportunity, and recent model changes across key products such as Leqembi, Spinraza, and Tysabri. Analyst Commentary Recent Street research on Biogen shows a wide spread of views on where the stock should trade, with price targets ranging from around US$150 to US$300.
Narrative-Update • Sep 03
BIIB: Tau Alzheimer’s And Immunology Pipeline Will Shape Balanced Future Prospects
Analysts have nudged their fair value estimate for Biogen higher from $227.59 to $236.22. This reflects updated models that give more weight to late stage pipeline assets like litifilimab and potential contributions from products such as Leqembi, Spinraza, and Tysabri, while also incorporating a slightly higher discount rate and a modestly richer future P/E assumption.Narrative-Update • Aug 19
BIIB: Alzheimer’s Trial And Safety Risks Will Likely Cap Re Rating Potential
Biogen’s updated analyst price target now reflects a fair value estimate of $180.58, up from $162.20, as analysts factor in a relatively stronger late stage pipeline (particularly around litifilimab and felzartamab) and adjust assumptions on revenue growth, discount rate, and future P/E multiples following recent upgrades and target raises across the Street. Analyst Commentary Street research on Biogen over recent months shows a broadly constructive stance on the stock, with many firms lifting price targets and, in some cases, upgrading ratings as they factor in the late stage pipeline, Leqembi developments, and the impact of the Apellis acquisition.
Narrative-Update • Aug 05
BIIB: Late Stage Neurology Readouts Will Drive Upside Through 2029
Biogen's analyst fair value estimate has shifted higher to $291.70 from $279.94 as analysts factor in a series of recent price target increases tied to Q2 earnings updates, evolving views on Leqembi and Spinraza, and the upcoming litifilimab and diranersen readouts. Analyst Commentary Recent research updates on Biogen point to a more constructive tone around the stock, with many bullish analysts tying their views to Q2 execution, the broader late stage pipeline, and evolving expectations for Leqembi, Spinraza, Tysabri, and the Apellis assets.Narrative-Update • Jul 22
BIIB: Tau Alzheimer’s Program And At-Home Alzheimer’s Regimen Will Drive Future Upside
Analysts have nudged their average price targets for Biogen higher, with the updated fair value estimate moving from about $219 to $228 as they factor in recent trial readouts, early Leqembi subQ approval, a slightly higher projected profit margin, a modestly lower assumed revenue growth rate, and a lower future P/E. Analyst Commentary Recent Street research on Biogen shows a mix of enthusiasm around the Alzheimer's pipeline and Leqembi franchise, paired with caution on execution risks, dose questions, and the pace of commercial uptake.Narrative-Update • Jul 08
BIIB: Alzheimer’s Trial Uncertainty Will Likely Undermine Recent Acquisition Optimism
Biogen's analyst fair value estimate has been raised from $150.59 to $162.20 as analysts factor in higher price targets, a slightly lower discount rate, and more constructive views on the pipeline and the potential for a stabilizing core business. Analyst Commentary Recent Street research on Biogen shows a mix of optimism around the pipeline and caution around execution, valuation, and the balance of risks.Narrative-Update • Jun 24
BIIB: Late Stage Neurology Readouts And Immunology Deals Will Drive Upside
Biogen's analyst price target edges higher, with a modest fair value move from about $279.24 to $279.94 as analysts factor in recent upgrades, revised models around the Apellis acquisition, and upcoming Alzheimer's data readouts such as diranersen at AAIC. Analyst Commentary Recent Street research on Biogen points to a cluster of constructive views around the Apellis acquisition, the Alzheimer’s franchise, and a broader late stage pipeline.Narrative-Update • Jun 09
BIIB: Late Stage Neurology And Immunology Pipeline Will Drive Future Upside
Analysts have nudged their Biogen fair value estimate higher by about $6 to roughly $279, citing a combination of pipeline updates, a steadier core business and revised expectations for margins, growth and future P/E multiples as reflected in recent price target changes across the Street. Analyst Commentary Recent research points to a clear shift toward more constructive views on Biogen, with several bullish analysts lifting price targets and upgrading ratings as they reassess the pipeline and core franchises.Narrative-Update • May 26
BIIB: Tau Alzheimer’s Data And EPS Upside Will Drive Future Upside
Biogen's updated analyst price target has shifted from about $206 to $219, as analysts weigh mixed but encouraging tau program data, potential EPS upside, and a modestly higher assumed future P/E multiple. Analyst Commentary Recent research views on Biogen cluster around mixed tau data, potential earnings power, and how much of that is already reflected in the stock's valuation.Narrative-Update • May 04
BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential
Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.Narrative-Update • Apr 20
BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism
Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.Narrative-Update • Apr 05
BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism
The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.Narrative-Update • Mar 22
BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism
Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.Narrative-Update • Mar 07
BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside
The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.Narrative-Update • Feb 21
BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk
The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.Analyseartikel • Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings
Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...Narrative-Update • Feb 07
BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential
Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.Narrative-Update • Jan 23
BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations
Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.Narrative-Update • Jan 09
BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook
Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.Narrative-Update • Dec 24
BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance
Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.Narrative-Update • Dec 10
BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead
Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.Narrative-Update • Nov 26
BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead
Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.Narrative-Update • Nov 12
BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025
Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.Narrative-Update • Oct 29
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.Narrative-Update • Oct 15
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.Narrative-Update • Sep 20
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.Narrative-Update • Sep 05
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$835m |
| Mar 31 2026 | n/a | n/a | US$1b |
| Dec 31 2025 | US$24m | US$2m | US$1b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$2b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | US$24m | US$2m | US$2b |
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$4m | US$2m | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$30m | US$154k | US$3b |
Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD23.65M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.74M).
Entschädigung vs. Einkommen: ChrisDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Chris Viehbacher (65 yo)
3.8yrs
Amtszeit
US$23,646,004
Vergütung
Mr. Christopher A. Viehbacher, also known as Chris, is the President, Chief Executive Officer & Director at Biogen Inc. since November 14, 2022. Mr. Viehbacher was President, Chief Executive Officer & Dire...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 3.8yrs | US$23.65m | 0.020% $ 6.5m | |
| Executive VP & CFO | 1.5yrs | US$5.81m | 0.0078% $ 2.5m | |
| Executive VP and Head of Pharmaceutical Operations & Technology | 4.6yrs | US$7.58m | 0.013% $ 4.3m | |
| Executive VP & Head of Development | 6.7yrs | US$7.57m | 0.0054% $ 1.7m | |
| VP, Chief Accounting Officer & Global Corporate Controller | 1.5yrs | keine Daten | 0.00091% $ 289.8k | |
| Chief Information Officer | 1.7yrs | keine Daten | keine Daten | |
| Head of Investor Relations | 1.8yrs | keine Daten | keine Daten | |
| Chief Legal Officer | less than a year | keine Daten | keine Daten | |
| Chief Communication Officer & Head of Corporate Affairs | 6.7yrs | keine Daten | keine Daten | |
| Executive VP & Head of Corporate Development | 3.4yrs | keine Daten | 0.0043% $ 1.4m | |
| Executive VP & Chief Human Resources Officer | 9.2yrs | US$5.08m | 0.015% $ 4.8m | |
| President & Head of North America | 9.2yrs | keine Daten | keine Daten |
3.6yrs
Durchschnittliche Betriebszugehörigkeit
55.5yo
Durchschnittliches Alter
Erfahrenes Management: BIIBDas Führungsteam des Unternehmens gilt als erfahren (3.6 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 3.8yrs | US$23.65m | 0.020% $ 6.5m | |
| Independent Director | 16.5yrs | US$439.95k | 0.0093% $ 2.9m | |
| Independent Director | 7.3yrs | US$462.45k | 0.0060% $ 1.9m | |
| Independent Director | 16.5yrs | US$454.95k | 0.016% $ 5.2m | |
| Independent Chair of the Board | 5.3yrs | US$457.45k | 0.0046% $ 1.5m | |
| Independent Director | 1.9yrs | US$439.95k | 0.00080% $ 254.7k | |
| Independent Director | 2.7yrs | US$447.45k | 0.0025% $ 799.2k | |
| Independent Director | 1.7yrs | US$439.95k | 0.0016% $ 509.5k | |
| Independent Director | 7.3yrs | US$459.95k | 0.0066% $ 2.1m | |
| Independent Director | 3.3yrs | US$439.95k | 0.0035% $ 1.1m |
4.5yrs
Durchschnittliche Betriebszugehörigkeit
66.5yo
Durchschnittliches Alter
Erfahrener Vorstand: BIIBDie Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/21 19:53 |
| Aktienkurs zum Tagesende | 2026/09/18 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Biogen Inc. wird von 61 Analysten beobachtet. 32 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |